Please login to the form below

Not currently logged in
Email:
Password:

Pharmexx get CQC accreditation

Pharmexx is the first UK CSO to be awarded accreditation by the CQC for its health management services business unit

Pharmexx is the first UK contract sales organisation (CSO) to be awarded accreditation by the Care Quality Commission (CQC) for its health management services business unit, which provides services to pharma and the NHS in the UK.

The review by the CQC certified that Pharmexx met the necessary level of safeguarding patient welfare and monitoring quality of service provision. The contract sales organisation also demonstrated that it has sufficient amounts of staffing with the right competencies, skills and experience to meet the needs of its clients.

Pharmexx is Europe's largest (CSO). Its health management service business unit was set up in early 2010.

Nigel Mansford, MD of Pharmexx, UK said: "In early 2010, we recognised a requirement to invest in the development of our healthcare managed service business. The pace of this investment was driven by the significant change to the UK market place and the feedback from our pharma and NHS customers to offer high-quality services that they were unable to find via other providers."

He continued: "The appointment of a high-quality and experienced team was the first step in the long pathway to becoming the first CSO to be CQC accredited. This is a tremendous and exciting time for our clients and for everyone involved with Pharmexx."

The CQC is the independent accreditation body of health and social care in England. It regulates the care provided by private healthcare companies as well as the NHS, local authorities and voluntary organisations.

11th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics